ArticleCell communication and signaling : CCS2026
Loss of CA12 drive proliferation and fibrosis in type i congenital pulmonary airway malformation via promoting abnormal activation of SHH signaling.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Congenital pulmonary airway malformation (CPAM), especially type I, is an uncommon developmental lung defect marked by abnormal proliferation of pseudostratified ciliated columnar epithelium (PCCE) and the presence of cystic lesions. Recent studies indicate that Sonic Hedgehog (SHH) signaling and carbonic anhydrase 12 (CA12) play essential roles in CPAM pathogenesis. This study investigates the interaction between SHH and CA12 in PCCE proliferation and fibrosis in type I CPAM. Cystic and surrounding healthy lung tissues were obtained from 10 pediatric patients with CPAM, and primary pseudostratified ciliated columnar epithelial cells were extracted. CA12 and SHH expressions were manipulated through overexpression and knockdown techniques, followed by detection of cell proliferation, cell cycle, and fibrosis. Results revealed that CA12 expression is significantly reduced, whereas SHH was overexpressed in type I CPAM cysts. CA12 overexpression inhibited PCCEC proliferation, fibrosis, and SHH signaling, as indicated by decreased Cyclin D1, Cyclin E1, and fibrosis marker (α-smooth muscle actin, Collagen I, and Collagen III) levels. Conversely, SHH knockdown suppressed proliferation and fibrosis, whereas SHH overexpression enhanced these processes. Mechanistically, CA12 modulated intracellular pH balance through transporters sodium bicarbonate cotransporter 1 (NBCn1) and monocarboxylate transporter 4 (MCT4), influencing SHH expression. Lactic acid treatment stimulated SHH signaling, increasing Gli-1, Gli-2, and fibrosis markers, and enhancing PCCEC proliferation. NBCn1 or MCT4 overexpression reversed the effects of CA12 knockdown, restoring pH balance and inhibiting SHH signaling. In conclusion, CA12 deficiency and SHH overexpression enhance PCCE proliferation and fibrosis in type I CPAM, with CA12 modulating SHH signaling by regulating intracellular acid-base equilibrium. These findings highlight CA12 and SHH as prospective therapeutic targets for CPAM management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.